Barclays Upgrades Chemours (NYSE:CC) to Hold

Chemours (NYSE:CC) was upgraded by equities research analysts at Barclays to a “hold” rating in a research report issued to clients and investors on Monday, Zacks reports.

CC has been the subject of a number of other reports. Mizuho reissued a “neutral” rating and set a $15.00 target price (down from $18.00) on shares of Chemours in a research note on Wednesday. Weiss Ratings lowered shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. BMO Capital Markets reduced their price target on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. UBS Group reduced their price target on shares of Chemours from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, October 5th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $16.00 price objective on shares of Chemours in a research report on Friday, October 9th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $18.09.

Chemours Stock Down 2.9%

Shares of Chemours stock opened at $12.81 on Monday. Chemours has a 1 year low of $10.44 and a 1 year high of $28.67. The business has a 50-day moving average of $14.79 and a two-hundred day moving average of $18.97. The company has a market capitalization of $1.93 billion, a P/E ratio of -6.71 and a beta of 1.41. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88.

Chemours (NYSE:CC) last released its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same period in the prior year, the business earned ($2.54) EPS. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. As a group, equities analysts predict that Chemours will post 0.84 EPS for the current year.

Insider Activity

In other news, CFO Shane Hostetter purchased 3,350 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were bought at an average cost of $14.94 per share, for a total transaction of $50,049.00. Following the completion of the acquisition, the chief financial officer directly owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of Chemours stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average cost of $15.53 per share, with a total value of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 8,663 shares of company stock worth $130,601 over the last three months. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Chemours

A number of large investors have recently bought and sold shares of CC. BlackRock Inc. bought a new position in shares of Chemours during the 2nd quarter worth approximately $477,769,000. Wolf Hill Capital Management LP bought a new stake in Chemours during the second quarter worth $59,698,056. Bank of New York Mellon Corp bought a new stake in Chemours during the second quarter worth $33,353,000. Legal & General Group Plc acquired a new stake in Chemours in the second quarter valued at $28,400,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Chemours in the second quarter valued at $18,119,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
• Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action

About Chemours

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.